Drugs / CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05242965 | Mar 2023 → Aug 2024 overdue | non-small cell lung carcinoma | University of Washington | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05242965 ↗ |
| Modality | Vaccine | “CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine” NCT05242965 ↗ |
| Route | Other | “Patients receive STEMVAC intradermally (ID)” NCT05242965 ↗ |
| Target | CDH3 | “The DNA used in this study contains instructions for your body to produce parts of the 5 proteins the investigators identified (CDH3, CD105, YB-1, MDM2 and SOX2).” NCT05242965 ↗ |
| Target | MDM2 | “The DNA used in this study contains instructions for your body to produce parts of the 5 proteins the investigators identified (CDH3, CD105, YB-1, MDM2 and SOX2).” NCT05242965 ↗ |
| Target | SOX2 | “The DNA used in this study contains instructions for your body to produce parts of the 5 proteins the investigators identified (CDH3, CD105, YB-1, MDM2 and SOX2).” NCT05242965 ↗ |